CI Investments Inc. Sells 30,603 Shares of Pfizer Inc. $PFE

CI Investments Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 10.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 272,197 shares of the biopharmaceutical company’s stock after selling 30,603 shares during the quarter. CI Investments Inc.’s holdings in Pfizer were worth $6,936,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in PFE. Peak Asset Management LLC boosted its holdings in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the period. Community Bank & Trust Waco Texas raised its position in Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares during the last quarter. Able Wealth Management LLC raised its position in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares during the last quarter. CVA Family Office LLC lifted its holdings in Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management grew its position in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 420 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

Shares of NYSE PFE opened at $26.61 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a 50-day moving average of $26.23 and a 200 day moving average of $25.45. The stock has a market cap of $151.31 billion, a P/E ratio of 19.57 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Argus raised Pfizer to a “Buy,” giving the stock near‑term analyst momentum that can attract flows. Pfizer (NYSE:PFE) Raised to “Buy” at Argus
• Positive Sentiment: Pfizer reported progress on PF‑07328948 (kidney function) Phase 1 work — a pipeline advancement that supports longer‑term product value and upside beyond current franchises. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones (PADCEV+Keytruda Phase 3 benefits and full FDA approval for a BRAFTOVI regimen) reshape growth prospects away from COVID‑era revenues — a material strategic positive for future revenue mix. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a tangible move toward Physical AI and factory automation that could improve throughput, quality, and costs over time. Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment
• Positive Sentiment: Market commentary continues to frame Pfizer as a defensive, high‑yield option (dividend yield cited as attractive), which supports demand in risk‑off environments. The Dividend Safe Harbor: 2 Stocks to Watch (PFE)
• Positive Sentiment: Analyst/market pieces highlight improving cash generation and active portfolio renewal, reinforcing a recovery narrative that could boost multiple expansion if sustained. Pfizer’s Quiet Cash Comeback Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Consensus analyst rating remains a “Hold” per a recent roundup — a signal that while sentiment is improving, broad analyst conviction is not yet uniformly bullish. Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Industry reports on AI in pharma manufacturing note Pfizer among large firms integrating AI — a positive trend but more structural and longer‑term than an immediate earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: NYSE floor events (bell‑ringing notices) are routine market color without company‑specific impact. NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Analyst Ratings Changes

A number of brokerages recently commented on PFE. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Morgan Stanley dropped their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Scotiabank began coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.